Advertisement

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma

Published:January 20, 2015DOI:https://doi.org/10.1016/j.ejca.2014.12.019

      Abstract

      Purpose

      A randomised, open label phase III trial was conducted to evaluate efficacy of nimotuzumab, a monoclonal antibody against epidermal growth factor receptor (EGF-R) added to standard therapy for newly diagnosed glioblastoma.

      Patients and methods

      149 glioblastoma patients stratified as with or without residual tumour were randomly assigned to receive either intravenous nimotuzumab 400 mg weekly added to standard radiochemotherapy followed by 400 mg biweekly after twelve weeks or standard radiochemotherapy. Progression status after 52 weeks (12moPFS) and progression-free survival (PFS) based on Macdonald criteria were co-primary and overall survival (OS), toxicity and quality of life secondary end-points.

      Results

      142 patients were evaluated for efficacy (per protocol cohort). 12moPFS was 25.6% in the experimental arm and 20.3% in the control group. In residual tumour patients (n = 81) median PFS was 5.6 versus 4.0 months, (hazard ratio (HR), 0.87; 95% confidence interval (CI), 0.55–1.37), for patients without residual tumour (n = 61) it was 10.6 versus 9.9 months, (HR, 1.01; 95% CI, 0.57–1.77). Median OS in patients with residual tumour was 19.5 versus 16.7 months, (HR, 0.90; 95% CI, 0.52–1.57; P = 0.7061), for patients without 23.3 versus 21.0 months (HR, 0.77; 95% CI, 0.41–1.44; P = 0.4068). A small cohort of MGMT non-methylated patients with residual tumour showed PFS of 6.2 versus 4.0 months (HR, 0.77; 95% CI, 0.35–1.67; P = 0.4997) and OS of 19.0 versus 13.8 months (HR, 0.66; 95% CI, 0.27–1.64; P = 0.3648). EGF-R amplification did not correlate with clinical efficacy of nimotuzumab. Nimotuzumab was well tolerated.

      Conclusion

      This study, albeit negative, contains hypothesis generating signals supporting evaluation of correlative, efficacy-predicting tumour parameters for nimotuzumab in the treatment of glioblastoma.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Downward J.
        • Yarden Y.
        • Mayes E.
        • et al.
        Close similarity of epidermal growth factor receptor and verb-B oncogene protein sequences.
        Nature. 1984; 307: 521-527
        • Caraglia M.
        • Marra M.
        • Meo G.
        • et al.
        EGF-R small inhibitors and anti-EGF-R antibodies: advantages and limits of a new avenue in anticancer therapy.
        Recent Pat Anticancer Drug Discov. 2006; 1: 209-222
        • Uhm J.H.
        • Ballman K.V.
        • Wu W.
        • et al.
        Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
        Int J Radiat Oncol Biol Phys. 2011; 80: 347-353
        • Brown P.D.
        • Krishnan S.
        • Sarkaria J.N.
        • et al.
        Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.
        J Clin Oncol. 2008; 26: 5603-5609
        • Neyns B.
        • Sadones J.
        • Joosens E.
        • et al.
        Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
        Ann Oncol. 2009; 20: 1596-1603
        • Wikstrand C.J.
        • Reist C.J.
        • Archer G.E.
        • et al.
        The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
        J Neurovirol. 1998; 4: 148-158
        • Kuan C.T.
        • Wikstrand C.J.
        • Bigner D.D.
        EGFRvIII as a promising target for antibody-based brain tumor therapy.
        Brain Tumor Pathol. 2000; 17: 71-78
        • Choi B.D.
        • Archer G.E.
        • Mitchell D.A.
        • et al.
        EGFRvIII-targeted vaccination therapy of malignant glioma.
        Brain Pathol. 2009; 19: 713-723
        • Talavera A.
        • Friemann R.
        • Gomez-Puerta S.
        • et al.
        Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
        Cancer Res. 2009; 69: 5851-5859
        • Solomon M.T.
        • Selva J.C.
        • Figueredo J.
        • et al.
        Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
        BMC Cancer. 2013; 13: 299
        • Bode U.
        • Massimino M.
        • Bach F.
        • et al.
        Nimotuzumab treatment of malignant gliomas.
        Expert Opin Biol Ther. 2012; 12: 1649-1659
        • Massimino M.
        • Bode U.
        • Biassoni V.
        • Fleischhack G.
        Nimotuzumab for pediatric diffuse intrinsic pontine gliomas.
        Expert Opin Biol Ther. 2011; 11: 247-256
        • Wolff J.E.
        • Rytting M.E.
        • Vats T.S.
        • et al.
        Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.
        J Neurooncol. 2012; 106: 391-397
        • Mateo C.
        • Moreno E.
        • Amour K.
        • et al.
        Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity.
        Immunotechnology. 1997; 3: 71-81
        • Stupp R.
        • Mason W.P.
        • van den Bent M.J.
        • et al.
        Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
        N Engl J Med. 2005; 352: 987-996
        • Macdonald D.R.
        • Cascino T.L.
        • Schold Jr., S.C.
        • Cairncross J.G.
        Response criteria for phase II studies of supratentorial malignant glioma.
        J Clin Oncol. 1990; 8: 1277-1280
        • van den Bent M.J.
        • Vogelbaum M.A.
        • Wen P.Y.
        • et al.
        End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s Criteria.
        J Clin Oncol. 2009; 27: 2905-2908
        • Wen P.Y.
        • Macdonald D.R.
        • Reardon D.A.
        • et al.
        Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.
        J Clin Oncol. 2010; 28: 1963-1972
        • Ramos T.C.
        • Figueredo J.
        • Catala M.
        • et al.
        Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
        Cancer Biol Ther. 2006; 5: 375-379
        • Mikeska T.
        • Bock C.
        • El-Maarri O.
        • et al.
        Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
        J Mol Diagn. 2007; 9: 368-381
        • Westphal M.
        • Hilt D.C.
        • Bortey E.
        • et al.
        A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.
        Neuro Oncol. 2003; 5: 79-88
        • Kunwar S.
        • Chang S.
        • Westphal M.
        • et al.
        Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
        Neuro Oncol. 2010; 12: 871-881
        • Stummer W.
        • van den Bent M.J.
        • Westphal M.
        Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion.
        Acta Neurochir (Wien). 2011; 153: 1211-1218
        • Armanios M.Y.
        • Grossman S.A.
        • Yang S.C.
        • et al.
        Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature.
        Neuro Oncol. 2004; 6: 259-263
        • Chen K.S.
        • Mitchell D.A.
        Monoclonal antibody therapy for malignant glioma.
        Adv Exp Med Biol. 2012; 746: 121-141
        • Faillot T.
        • Magdelenat H.
        • Mady E.
        • et al.
        A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas.
        Neurosurgery. 1996; 39: 478-483
        • Lampson L.A.
        Monoclonal antibodies in neuro-oncology: getting past the blood–brain barrier.
        MAbs. 2011; 3: 153-160
        • Ellingson B.M.
        • Cloughesy T.F.
        • Lai A.
        • et al.
        Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab.
        Neuro Oncol. 2011; 13: 401-409
        • Levin V.A.
        • Bidaut L.
        • Hou P.
        • et al.
        Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.
        Int J Radiat Oncol Biol Phys. 2011; 79: 1487-1495
        • Viloria-Petit A.
        • Crombet T.
        • Jothy S.
        • et al.
        Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.
        Cancer Res. 2001; 61: 5090-5101
        • Crombet-Ramos T.
        • Rak J.
        • Perez R.
        • Viloria-Petit A.
        Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody.
        Int J Cancer. 2002; 101: 567-575
        • Eller J.L.
        • Longo S.L.
        • Kyle M.M.
        • et al.
        Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo.
        Neurosurgery. 2005; 56 ([discussion 162]): 155-162
        • Ferris R.L.
        • Jaffee E.M.
        • Ferrone S.
        Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
        J Clin Oncol. 2010; 28: 4390-4399
        • Lu H.
        • Dietsch G.N.
        • Matthews M.A.
        • et al.
        VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
        Clin Cancer Res. 2012; 18: 499-509
        • Fukai J.
        • Nishio K.
        • Itakura T.
        • Koizumi F.
        Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III.
        Cancer Sci. 2008; 99: 2062-2069
        • Jackson C.
        • Ruzevick J.
        • Phallen J.
        • et al.
        Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment.
        Clin Dev Immunol. 2011; 2011: 732413
        • Donson A.M.
        • Birks D.K.
        • Schittone S.A.
        • et al.
        Increased immune gene expression and immune cell infiltration in high-grade astrocytoma distinguish long-term from short-term survivors.
        J Immunol. 2012; 189: 1920-1927
        • Yu J.S.
        • Lee P.K.
        • Ehtesham M.
        • et al.
        Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium.
        J Neurooncol. 2003; 64: 55-61
        • Hegi M.E.
        • Rajakannu P.
        • Weller M.
        Epidermal growth factor receptor: a re-emerging target in glioblastoma.
        Curr Opin Neurol. 2012; 25: 774-779